{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:11:56Z","timestamp":1791277916617,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2013,2,18]],"date-time":"2013-02-18T00:00:00Z","timestamp":1361145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,2,18]],"date-time":"2013-02-18T00:00:00Z","timestamp":1361145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1038\/leu.2013.51","type":"journal-article","created":{"date-parts":[[2013,2,18]],"date-time":"2013-02-18T09:34:44Z","timestamp":1361180084000},"page":"1511-1519","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":117,"title":["Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib"],"prefix":"10.1038","volume":"27","author":[{"given":"F","family":"Efficace","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Baccarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Breccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Cottone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Alimena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G L","family":"Deliliers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Barat\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Specchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Di Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Luciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Turri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Stagno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Dabusti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Bergamaschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Leoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M P","family":"Simula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Levato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Fava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Veneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Sica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Rambaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Rosti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Vignetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Mandelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,2,18]]},"reference":[{"key":"BFleu201351_CR1","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1200\/JCO.2011.34.7146","volume":"29","author":"M Bjorkholm","year":"2011","unstructured":"Bjorkholm M, Ohm L, Eloranta S, Derolf A, Hultcrantz M, Sjoberg J et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol 2011; 29: 2514\u20132520.","journal-title":"J Clin Oncol"},{"key":"BFleu201351_CR2","doi-asserted-by":"publisher","first-page":"5327","DOI":"10.1200\/JCO.2010.33.2742","volume":"28","author":"MG Kris","year":"2010","unstructured":"Kris MG, Benowitz SI, Adams S, Diller L, Ganz P, Kahlenberg MS et al. Clinical cancer advances 2010: annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol 2010; 28: 5327\u20135347.","journal-title":"J Clin Oncol"},{"key":"BFleu201351_CR3","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1182\/asheducation-2011.1.128","volume":"100","author":"A Hochhaus","year":"2011","unstructured":"Hochhaus A . Managing chronic myeloid leukemia as a chronic disease. American Society of Hematology Educational Program Book. Hematology 2011; 100: 128\u2013135.","journal-title":"Hematology"},{"key":"BFleu201351_CR4","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/jnci\/djr060","volume":"103","author":"C Gambacorti-Passerini","year":"2011","unstructured":"Gambacorti-Passerini C, Antolini L, Mahon F-X, Guilhot F, Deininger M, Fava C et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. JNCI 2011; 103: 553\u2013561.","journal-title":"JNCI"},{"key":"BFleu201351_CR5","doi-asserted-by":"publisher","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","volume":"17","author":"F Efficace","year":"2011","unstructured":"Efficace F, Baccarani M, Breccia M, Alimena G, Rosti G, Cottone F et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 2011; 17: 4554\u20134560.","journal-title":"Blood"},{"key":"BFleu201351_CR6","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/cncr.25648","volume":"117","author":"J Pinilla-Ibarz","year":"2011","unstructured":"Pinilla-Ibarz J, Cortes J, Mauro MJ . Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: definitions and clinical implications. Cancer 2011; 117: 688\u2013697.","journal-title":"Cancer"},{"key":"BFleu201351_CR7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.critrevonc.2011.02.007","volume":"81","author":"F Efficace","year":"2012","unstructured":"Efficace F, Cocks K, Breccia M, Sprangers M, Meyers CA, Vignetti M et al. Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: inclusion of quality of life and other patient-reported outcomes. Crit Rev Oncol Hematol 2012; 81: 123\u2013135.","journal-title":"Crit Rev Oncol Hematol"},{"key":"BFleu201351_CR8","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.leukres.2012.10.021","volume":"37","author":"F Efficace","year":"2013","unstructured":"Efficace F, Cardoni A, Cottone F, Vignetti M, Mandelli F . Tyrosine-kinase inhibitors and patient-reported outcomes in chronic myeloid leukemia: a systematic review. Leuk Res 2013; 37: 206\u2013213.","journal-title":"Leuk Res"},{"key":"BFleu201351_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1634\/theoncologist.8-suppl_1-5","volume":"8","author":"H Flechtner","year":"2003","unstructured":"Flechtner H, Bottomley A . Fatigue and quality of life: lessons from the real world. Oncologist 2003; 8: 5\u20139.","journal-title":"Oncologist"},{"key":"BFleu201351_CR10","unstructured":"National Comprehensive Cancer Network (NCCN). Practice guidelines in oncology. Cancer-related fatigue, V.1.2012."},{"key":"BFleu201351_CR11","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3322\/CA.2007.0001","volume":"58","author":"SS Coughlin","year":"2008","unstructured":"Coughlin SS . Surviving cancer or other serious illness: a review of individual and community resources. CA Cancer J Clin 2008; 58: 60\u201364.","journal-title":"CA Cancer J Clin"},{"key":"BFleu201351_CR12","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1002\/pon.1390","volume":"18","author":"V Cicero","year":"2009","unstructured":"Cicero V, Lo Coco G, Gullo S, Lo Verso G . The role of attachment dimensions and perceived social support in predicting adjustment to cancer. Psychooncology 2009; 18: 1045\u20131052.","journal-title":"Psychooncology"},{"key":"BFleu201351_CR13","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1200\/JCO.2005.03.2011","volume":"24","author":"I Iacobucci","year":"2006","unstructured":"Iacobucci I, Rosti G, Amabile M, Poerio A, Soverini S, Cilloni D et al. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. J Clin Oncol 2006; 24: 454\u2013459.","journal-title":"J Clin Oncol"},{"key":"BFleu201351_CR14","first-page":"241","volume-title":"Outcomes assessment in cancer: measures, methods and applications","author":"B Zebrack","year":"2005","unstructured":"Zebrack B, Cella D . Evaluating quality of life in cancer survivors. In: Lipscomb J, Gotay C, Snyder C, eds. Outcomes assessment in cancer: measures, methods and applications. Cambridge University Press: Cambridge, UK, pp 241\u2013263 2005."},{"key":"BFleu201351_CR15","doi-asserted-by":"crossref","unstructured":"Ware JE, Sherbourne CD . The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30: 473\u2013483.","DOI":"10.1097\/00005650-199206000-00002"},{"key":"BFleu201351_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0885-3924(96)00274-6","volume":"13","author":"SB Yellen","year":"1997","unstructured":"Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E . Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 1997; 13: 63\u201374.","journal-title":"J Pain Symptom Manage"},{"key":"BFleu201351_CR17","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/cncr.10245","volume":"94","author":"D Cella","year":"2002","unstructured":"Cella D, Lai JS, Chang CH, Peterman A, Slavin M . Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 2002; 94: 528\u2013538.","journal-title":"Cancer"},{"key":"BFleu201351_CR18","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3324\/haematol.2009.010215","volume":"95","author":"F Efficace","year":"2010","unstructured":"Efficace F, Breccia M, Baccarani M, Alimena G, Lambertenghi Deliliers G, Specchia G et al. Development and feasibility of a patient-reported symptom checklist for chronic myeloid leukemia patients [abstract]. Haematologica 2010; 95: 189 Abstract 0465.","journal-title":"Haematologica"},{"key":"BFleu201351_CR19","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1207\/s15327752jpa5503&4_17","volume":"55","author":"GD Zimet","year":"1990","unstructured":"Zimet GD, Powell SS, Farley GK, Werkman S, Berkoff KA . Psychometric characteristics of the multidimensional scale of perceived social support. J Pers Assess 1990; 55: 610\u2013617.","journal-title":"J Pers Assess"},{"key":"BFleu201351_CR20","unstructured":"Apolone G, Mosconi P, Ware JE Questionario sullo stato di salute SF-36. Manuale d\u2019uso e guida all\u2019interpretazione dei risultati Versione Italiana Guerini e Associati Editore, Milan 1997."},{"key":"BFleu201351_CR21","doi-asserted-by":"crossref","unstructured":"Harrell FE Regression modeling strategies, with applications to linear models. Logistic Regression, and Survival Analysis Springer: New York, 2001.","DOI":"10.1007\/978-1-4757-3462-1"},{"key":"BFleu201351_CR22","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/1467-9876.00155","volume":"48","author":"W Sauerbrei","year":"1999","unstructured":"Sauerbrei W . The use of resampling methods to simplify regression models in medical statistics. J R Stat Soci ser C (Appl Stat) 1999; 48: 313\u2013329.","journal-title":"J R Stat Soci ser C (Appl Stat)"},{"key":"BFleu201351_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4899-4541-9","volume-title":"An introduction to the bootstrap","author":"B Efron","year":"1993","unstructured":"Efron B, Tibshirani R . An introduction to the bootstrap. Chapman and Hall: London, 1993."},{"key":"BFleu201351_CR24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1177\/009286150303700105","volume":"37","author":"J Sloan","year":"2011","unstructured":"Sloan J, Symonds T, Vargas-Chanes D, Fridley B . Practical guidelines for assessing the clinical significance of health-related quality of life changes within clinical trials. Drug Inf J 2011; 37: 23\u201331.","journal-title":"Drug Inf J"},{"key":"BFleu201351_CR25","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/annonc\/mdh235","volume":"15","author":"D Cella","year":"2004","unstructured":"Cella D, Kallich J, McDermott A, Xu X . The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol 2004; 15: 979\u2013986.","journal-title":"Ann Oncol"},{"key":"BFleu201351_CR26","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/sj.leu.2404576","volume":"21","author":"SM Alibhai","year":"2007","unstructured":"Alibhai SM, Leach M, Kowgier ME, Tomlinson GA, Brandwein JM, Minden MD . Fatigue in older adults with acute myeloid leukemia: predictors and associations with quality of life and functional status. Leukemia 2007; 21: 845\u2013848.","journal-title":"Leukemia"},{"key":"BFleu201351_CR27","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1200\/JCO.2003.12.154","volume":"21","author":"EA Hahn","year":"2003","unstructured":"Hahn EA, Glendenning GA, Sorensen MV, Hudgens SA, Druker BJ, Guilhot F et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol 2003; 21: 2138\u20132146.","journal-title":"J Clin Oncol"},{"key":"BFleu201351_CR28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/jnci\/94.1.39","volume":"94","author":"PA Ganz","year":"2002","unstructured":"Ganz PA, Desmond KA, Leedham B, Rowland JH, Meyerowitz BE, Belin TR . Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. J Natl Cancer Inst 2002; 94: 39\u201349.","journal-title":"J Natl Cancer Inst"},{"key":"BFleu201351_CR29","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s00520-005-0856-x","volume":"14","author":"JW Lim","year":"2006","unstructured":"Lim JW, Zebrack B . Social networks and quality of life for long-term survivors of leukemia and lymphoma. Support Care Cancer 2006; 14: 185\u2013192.","journal-title":"Support Care Cancer"},{"key":"BFleu201351_CR30","doi-asserted-by":"crossref","unstructured":"Nazha A, Williams L, Kantarjian H, Ault P, Garcia-Gonzalez A, Williams J et al. Fatigue in chronic myelogenous leukemia patients (pts) treated with tyrosine kinase inhibitors (TKI). Blood (ASH Annu Meet Abstr) 2011; 118, Abstract 3785.","DOI":"10.1182\/blood.V118.21.3785.3785"},{"key":"BFleu201351_CR31","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.jpainsymman.2010.05.011","volume":"41","author":"DJ Wantland","year":"2011","unstructured":"Wantland DJ, Mullan JP, Holzemer WL, Portillo CJ, Bakken S, McGhee EM . Additive effects of numbness and muscle aches on fatigue occurrence in individuals with HIV\/AIDS who are taking antiretroviral therapy. J Pain Symptom Manage 2011; 41: 469\u2013477.","journal-title":"J Pain Symptom Manage"},{"key":"BFleu201351_CR32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/annonc\/mdn537","volume":"20","author":"O Minton","year":"2009","unstructured":"Minton O, Stone P . A systematic review of the scales used for the measurement of cancer-related fatigue (CRF). Ann Oncol 2009; 20: 17\u201325.","journal-title":"Ann Oncol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu201351.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201351","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201351.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T12:31:18Z","timestamp":1648729878000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu201351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,18]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["BFleu201351"],"URL":"https:\/\/doi.org\/10.1038\/leu.2013.51","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,18]]},"assertion":[{"value":"17 January 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Consultant or advisory role: FE, Mi Ba, MB, GR, CB (Novartis and Bristol Myers Squibb); research funding: FE, GR, PL (Novartis); honoraria: Mi Ba (Novartis, Bristol Myers Squibb, Pfizer and Ariad); expert testimony: DT (Novartis and Bristol Myers Squibb); AR (Novartis); other remuneration: DT (Novartis and Bristol Myers Squibb).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}